ICON (ICLR) Akcija Цена

ICON PLC, also known as ICON, is a well-established global provider of clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 in Dublin, Ireland, ICON has since expanded its operations worldwide, with offices in over 40 countries. The company offers various services, including clinical trial management, data management and analysis, regulatory support, and post-market surveillance. With a strong focus on innovation and expertise, ICON has successfully collaborated with numerous healthcare organizations to accelerate the development of innovative therapies and improve patient outcomes. Due to its vast experience and industry reputation, ICON PLC continues to be a trusted partner in advancing healthcare solutions globally.

The business model of ICON PLC is centered around providing clinical research services to pharmaceutical, biotechnology, and medical device companies. ICON offers a range of services including clinical trial management, data collection and analysis, regulatory consulting, and patient recruitment. They help their clients with the development and commercialization of new drugs and treatments by conducting clinical trials and ensuring regulatory compliance. With a strong focus on innovation and expertise in the field, ICON PLC has established itself as a trusted partner for the life sciences industry.

ICON PLC is primarily active in the pharmaceutical, biotechnology, and medical device industries.

ICON PLC, a leading clinical research organization, has achieved significant milestones throughout its history. The company's accomplishments include becoming a key player in the development and execution of clinical trials worldwide. ICON PLC has successfully expanded its global footprint, delivering exceptional services in over 100 countries. With a strong focus on innovation and technology, the company has pioneered industry-leading solutions to enhance clinical trial processes and improve patient outcomes. ICON PLC's dedication to excellence has resulted in numerous accolades and recognition within the pharmaceutical and biotechnology industries. By consistently delivering high-quality results and establishing strategic partnerships, ICON PLC has solidified its reputation as a trusted and influential player in the field of clinical research.

ICON PLC is primarily present in various countries and regions globally. With a strong international presence, the company operates in multiple key markets, including the United States, United Kingdom, Ireland, Europe, Asia-Pacific, and the Middle East. This global footprint enables ICON PLC to cater to clients worldwide and deliver its comprehensive range of professional services.

ICON PLC is a leading global provider of clinical research services to pharmaceutical, biotechnology, and medical device industries. ICON PLC is guided by a set of core values and corporate philosophy that focuses on innovation, integrity, collaboration, and excellence. The company's commitment to delivering high-quality research and development solutions, while maintaining ethical practices, has made it a trusted partner for successful clinical trials. With its dedication to advancing healthcare and improving patient outcomes, ICON PLC continues to be a respected and influential player in the industry.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 170,64 USD za akciju ICON (medijana: 175,00 USD), što znači -20,3 % u odnosu na poslednju cenu. Konsenzus se zasniva na 24 ocena.

ICON Циљне цене аналитичара 2026

24 analitičara trenutno ocenjuje akciju ICON: 15 preporučuje kupovinu, 8 držanje i 1 prodaju. Za 2026 analitičari očekuju da ICON ostvari prihod 8,14 Млрд USD i zaradu po akciji 11,46 USD.

ICON Циљне цене аналитичара 2026

Po trenutnom kursu akcija ICON kotira 189,29 EUR (211,36 USD).

Akcija ICON (ICLR) kotira na 4 berze, uključujući: NASDAQ (ICLR), Frankfurt (IJF.F), München (IJF.MU), Düsseldorf (IJF.DU).

ICON plc is a leading global company in the field of clinical research and development of pharmaceuticals. It offers a wide range of services in clinical trials, consulting, strategy development, laboratory analysis, and data management. The company is divided into three main business areas: clinical development services, laboratory analysis, and data management. It works closely with its customers and partners to develop groundbreaking medications and treatments. ICON is known for its Enterprise Laboratory Information Management System (LIMS) and EDC solutions. It has a robust business model and is well-positioned for future growth.

očekivana prihod od ICON je 8,14 Млрд USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od ICON je 877,18 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za ICON je trenutno 18,45. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije ICON.

Odnos cene i prihoda (KUV) za ICON je trenutno 1,99. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju ICON.

Eulpool score kvaliteta za ICON je 2/10.

ISIN za ICON je IE0005711209. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za ICON je 932242. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za ICON je ICLR. Simbol tikera se koristi za trgovinu akcijama ICON na berzanskom tržištu.